In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries, Australia, New Zealand, and China.
Tedizolid is an oxazolidinone with an antimicrobial in vitro potency advantage against Gram-positive bacterial pathogens compared to other currently marketed drugs in this class, including linezolid. Tedizolid was compared to linezolid when tested against Staphylococcus aureus and Streptococcus pneumoniae isolates collected from countries in Latin America and the Asia-Pacific. Isolates were tested by broth microdilution susceptibility methods against tedizolid, linezolid, and non-class comparators in accordance with the Clinical and Laboratory Standards Institute (CLSI) guidelines. The activity of tedizolid against S. aureus was potent and consistent in Latin America (MIC90, 0.5 mg/L), Australia and New Zealand (MIC90, 0.25 mg/L), and China (MIC90, 0.5 mg/L). Based on MIC90results, tedizolid was four- to eight-fold more active than linezolid against S. aureus, including both methicillin-susceptible and -resistant isolates. Only two tedizolid non-susceptible strains were observed; both had intermediate minimum inhibitory concentration (MIC) values of 1 mg/L, for which the MICs of linezolid was higher (≥2 mg/L). Tedizolid (MIC90, 0.25 mg/L) was four-fold more potent than linezolid (MIC90, 1 mg/L) against S. pneumoniae in all countries that provided isolates. The findings from this study support the global clinical development of tedizolid for Gram-positive infections.
International Health Management Associates, Inc., 2122 Palmer Drive, Schaumburg, IL, 60173, USA. dbiedenbach@ihmainc.com.
D J
DJ
Biedenbach
International Health Management Associates, Inc., 2122 Palmer Drive, Schaumburg, IL, 60173, USA.
S K
SK
Bouchillon
International Health Management Associates, Inc., 2122 Palmer Drive, Schaumburg, IL, 60173, USA.
B
B
Johnson
Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.
J
J
Alder
International Health Management Associates, Inc., 2122 Palmer Drive, Schaumburg, IL, 60173, USA.
D F
DF
Sahm
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D044362:Australasia; D002681:China; D006801:Humans; D007843:Latin America; D000069349:Linezolid / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D010755:Organophosphates / Q000494:pharmacology*; D010080:Oxazoles / Q000494:pharmacology*; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification*; D013296:Streptococcus pneumoniae / Q000187:drug effects* / Q000302:isolation & purification*
D000900:Anti-Bacterial Agents; D010755:Organophosphates; D010080:Oxazoles; D000069349:Linezolid; C515040:tedizolid phosphate
J Antimicrob Chemother. 2016 Jan;71(1):152-5
26476277
Clin Infect Dis. 2014 Jan;58 Suppl 1:S1-3
24343826
Clin Infect Dis. 2015 Oct 15;61(8):1315-21
26105167
Ann Lab Med. 2015 Sep;35(5):523-30
26206690
J Antimicrob Chemother. 2015 Aug;70(8):2199-202
25921512
Lancet Infect Dis. 2014 Aug;14 (8):696-705
24909499
Expert Opin Investig Drugs. 2012 Apr;21(4):515-22
22324973
Antimicrob Agents Chemother. 2013 Aug;57(8):4061-3
23733472
Diagn Microbiol Infect Dis. 2015 Feb;81(2):112-8
25488274
J Antimicrob Chemother. 2012 Jan;67(1):167-9
21954458
Infect Drug Resist. 2015 Apr 22;8:75-82
25960671
Antimicrob Agents Chemother. 2014 Nov;58(11):6949-52
25136008
Clin Infect Dis. 2014 Jan;58 Suppl 1:S51-7
24343833
Clin Infect Dis. 2008 Mar 15;46(6):787-94
18266611
Drugs. 2015 Feb;75(3):253-70
25673021
Antimicrob Agents Chemother. 2015 Oct;59(10):6262-5
26248355
Antimicrob Agents Chemother. 2015 Feb;59(2):864-71
25421472
Infect Dis Ther. 2015 Feb 24;:null
25708156
Antimicrob Agents Chemother. 2013 Jun;57(6):2892-5
23571550